Meeting
2013 ASCO Annual Meeting
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.
Authors
Deirdre Jill Cohen
New York University Cancer Institute, New York, NY
Deirdre Jill Cohen , Paul J. Christos , Hedy Lee Kindler , Daniel Virgil Thomas Catenacci , Tanios B. Bekaii-Saab , Sanaa Tahiri , Yelena Yuriy Janjigian , Michael K. Gibson , Emily Chan , Lakshmi Rajdev , Susan Urba , James Lloyd Wade , Peter Kozuch , Erica Love , Katherine Vandris , Naoko Takebe , Howard S. Hochster , Joseph A. Sparano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT00982592
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4011)
DOI
10.1200/jco.2013.31.15_suppl.4011
Abstract #
4011
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.
First Author: Deirdre Cohen
Poster
2011 ASCO Annual Meeting
A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376).
First Author: D. J. Cohen
Poster
2020 ASCO Virtual Scientific Program
Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
First Author: Ramon Jin
Poster
2017 Gastrointestinal Cancers Symposium
A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.
First Author: Rongbo Lin